Statistics from Altmetric.com
Synovitis, acne, palmoplantar pustulosis, hyperostosis and osteitis (SAPHO) syndrome is a rare entity that involves the skin, bones and joints. The estimated prevalence of SAPHO syndrome is lower than 1/10 000.1 The real prevalence may be underestimated because of lack of typical symptoms.2 Bone is one of the critical affected organs for SAPHO. The most common site is the anterior chest wall (65%–90%), followed by the thoracic spine.1 However, the effects of SAPHO syndrome on bone loss or osteoporosis have not been clarified. We performed a case–control study to show bone loss in patients with SAPHO syndrome in a Chinese population.
From June 2014 to August 2019, a total of 27 new-onset SAPHO patients were included in the study after excluding patients who had been diagnosed for more than 6 months and who were younger than 25 years old. The diagnosis of SAPHO syndrome was based on clinical symptoms and radiological examinations.2 The diagnosis is based on the presence of at least one of four features: (1) osteoarticular manifestations with severe acne; (2) osteoarticular manifestations with palmoplantar pustulosis; (3) hyperostosis with or without skin lesions; (4) recurrent multifocal chronic osteomyelitis involving the axial or peripheral skeleton, with or without skin lesions. Two or three age-matched and gender-matched control subjects who underwent chest CT scan for physical …
Handling editor Josef S Smolen
Correction notice This article has been corrected since it published Online First. The co-corresponding author has been added.
Contributors XC and ZW contributed to the design of the project interpretation and analysis of the data, writing of the manuscript and critical revision of the manuscript. MW and WC contributed to data collection, interpretation and data analysis, and drafting of the manuscript. All authors approved the final manuscript.
Funding This study was received supports from National Natural Science foundation of China (No. 81773460, 81102148), Peak academic talent training fund of Jiangsu Province Hospital of Chinese Medicine (y2018rc04); Science and Technology Development Plan fund of Chinese Medicine of Jiangsu Province (ZD201907).
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.